IW-1701
C1701-202
Phase 2 small_molecule completed
Quick answer
IW-1701 for Sickle Cell Disease is a Phase 2 program (small_molecule) at Cyclerion Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cyclerion Therapeutics
- Indication
- Sickle Cell Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed